Revolution Medicines, Inc. (RVMD) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Redwood City, CA, United States. Der aktuelle CEO ist Mark A. Goldsmith.
RVMD hat IPO-Datum 2020-02-13, 616 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $29.13B.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel therapies targeting RAS-addicted cancers. The company's pipeline includes several investigational programs, such as RMC-4630, an SHP2 inhibitor currently in Phase 1/2 trials for solid tumors including gynecologic and colorectal cancers, as well as RMC-5845, RMC-5552, RMC-6291, and RMC-6236, which target various components of RAS signaling pathways. Revolution Medicines has established a collaboration with Sanofi for the research and development of SHP2 inhibitors. Founded in 2014 and based in Redwood City, California, the company is advancing precision medicine approaches to address cancers driven by RAS mutations.
